Texas Health Harris Methodist Hospital Southwest Fort Worth
Texas Health Harris Methodist Hospital Southwest Fort Worth was paid $5.20M by Medicaid between Oct 2020 and Nov 2024, across 83 billing codes. Its largest line is 99284, emergency room visit (serious) — 41% of everything it billed.
FORT WORTH, TX 76132
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,947 | $75K | |
| 2021 | 39,006 | $1.09M | |
| 2022 | 48,873 | $1.53M | |
| 2023 | 44,066 | $1.82M | |
| 2024incomplete | 15,405 | $682K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 41% | 13,046 | 11,966 | $2.12M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 19,074 | 18,106 | $954K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.4% | 2,396 | 2,319 | $226K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.8% | 1,647 | 1,523 | $200K |
| 80053 | Comprehensive metabolic panel | 3.8% | 14,684 | 13,089 | $196K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.1% | 3,460 | 3,348 | $161K |
| 59025 | Fetal non-stress test | 2.9% | 2,475 | 2,193 | $152K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 17,876 | 15,664 | $146K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.5% | 6,614 | 6,347 | $130K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 1,498 | 1,440 | $74K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 3,061 | 2,753 | $74K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 3,098 | 2,782 | $72K |
71 more codes
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.3% | 1,417 | $68K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.3% | 305 | $68K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 396 | $59K |
| 81001 | <1% | 12,929 | $47K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,305 | $43K |
| 76801 | <1% | 586 | $39K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 670 | $37K |
| 87631 | <1% | 228 | $31K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,028 | $27K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,028 | $27K |
| 87800 | <1% | 768 | $25K | |
| 84703 | <1% | 3,199 | $23K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 230 | $19K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 220 | $17K |
| CP007 | <1% | 351 | $16K | |
| 84484 | <1% | 2,169 | $14K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,347 | $13K |
| 83880 | <1% | 802 | $13K | |
| 84702 | <1% | 991 | $10K | |
| 83690 | <1% | 2,170 | $9K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,726 | $8K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,315 | $8K |
| 83605 | <1% | 1,469 | $7K | |
| 81025 | <1% | 1,073 | $7K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 120 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,160 | $5K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 71 | $4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 80 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 795 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 914 | $3K |
| 84112 | <1% | 15 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 761 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 544 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 787 | $2K |
| 87040 | <1% | 572 | $2K | |
| 94760 | <1% | 308 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 61 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 180 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,893 | $2K |
| 84145 | <1% | 105 | $1K | |
| 86901 | <1% | 656 | $1K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 13 | $1K |
| 87634 | <1% | 12 | $758.62 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 945 | $738.68 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $555.53 |
| 96376 | <1% | 298 | $482.98 | |
| 85379 | <1% | 59 | $370.62 | |
| 85610 | <1% | 162 | $344.26 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 362 | $330.80 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 17 | $297.76 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14 | $294.75 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 708 | $285.75 |
| 0352U | <1% | 77 | $228.20 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 331 | $165.14 |
| 85730 | <1% | 35 | $111.20 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 129 | $90.27 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 20 | $88.06 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 248 | $62.00 |
| J2704 | Injection, propofol, 10 mg | <1% | 63 | $54.74 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 13 | $51.30 |
| 86900 | <1% | 29 | $48.17 | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 37 | $40.35 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 112 | $38.36 |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,652 | $38.22 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 17 | $8.80 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 27 | $8.61 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 126 | $6.58 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 15 | $5.28 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 14 | $1.26 |
| A9270 | Non-covered item or service | <1% | 3,006 | $0.57 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 71 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Texas Health Harris Methodist Hospital Fort Worth | Fort Worth, TX | $13.83M |
| Texas Health Arlington Memorial Hospital | Arlington, TX | $8.23M |
| Texas Health Presbyterian Hospital Dallas | Dallas, TX | $5.33M |
| Texas Health Presbyterian Hospital Kaufman | Kaufman, TX | $4.09M |
| Texas Health Presbyterian Hospital Denton | Denton, TX | $3.84M |
| Texas Health Harris Methodist Hospital Stephenville | Stephenville, TX | $3.69M |
| Texas Health Harris Methodist Hospital Hurst-Euless-Bedford | Bedford, TX | $3.57M |
| Texas Health Presbyterian Hospital Plano | Plano, TX | $2.32M |
| Texas Health Harris Methodist Hospital Cleburne | Cleburne, TX | $2.31M |
| Texas Health Harris Methodist Hospital Azle | Azle, TX | $2.14M |
| Texas Health Harris Methodist Hospital Alliance | Fort Worth, TX | $986K |
| Texas Health Presbyterian Hospital Allen | Allen, TX | $965K |
| Texas Health Hospital Frisco | Frisco, TX | $473K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.